0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Influence of Digoxin Immune Fab Therapy and Renal Dysfunction on the Disposition of Total and Free Digoxin

Michael R. Ujhelyi; Sylvie Robert; Doyle M. Cummings; Robert D. Colucci; Paul J. Green; Jeffrey Sailstad; Peter H. Vlasses; and Barbara J. Zarowitz
[+] Article and Author Information

From Hartford Hospital and University of Connecticut, Hartford and Storrs, Connecticut; College of Pharmacy, Henry Ford Hospital and Wayne State University, Detroit, Michigan; East Carolina University School of Medicine, Greenville, North Carolina; Jefferson Medical College, Philadelphia, Pennsylvania; University Hospital Consortium, Oak Brook, Illinois; Wellcome Research Laboratories, Research Triangle Park, North Carolina. Requests for Reprints: Michael R. Ujhelyi, PharmD, College of Pharmacy, University of Cincinnati Medical Center, 3223 Eden Avenue, Cincinnati, OH 45267-0004. Grant Support: By Baxter Dade Healthcare Company. Acknowledgments: The authors thank Thomas L. Wenger, MD, for his critical review of this manuscript.


Copyright 2004 by the American College of Physicians


Ann Intern Med. 1993;119(4):273-277. doi:10.7326/0003-4819-119-4-199308150-00004
Text Size: A A A

Objective: To characterize the disposition of total and free serum digoxin following the administration of digoxin Fab antibody in patients with varying degrees of renal function.

Design: Observational study of pharmacokinetics and pharmacodynamics.

Setting: Critical care and telemetry units of two university-affiliated teaching institutions, Hartford Hospital and Henry Ford Hospital.

Patients: Fourteen digoxin-intoxicated patients (baseline total digoxin > 3.2 nmol/mL) with mean (SD) serum creatinine of 380.1 212.2 mol/L who received digoxin Fab antibody therapy.

Measurements: Serum was drawn every 12 to 24 hours for 80 to 327 hours after Fab administration. Total and free digoxin were assayed in serum by fluorescence polarization immunoassay or modified immunofluorometric assay.

Results: Before Fab was administered, total digoxin ranged from 3.5 to 10.5 nmol/mL. After treatment with Fab, total digoxin increased rapidly to a mean (SD) maximum of 51.8 22.7 nmol/mL and decreased to 7.2 4.7 nmol/mL at the last measurement. Total digoxin was eliminated in a two-phase fashion. The half-life of the initial phase of total digoxin decline was 11.6 4.1 hours, and the half-life of the second or terminal elimination phase was 118 57 hours. Free digoxin levels decreased rapidly following Fab therapy, to a mean nadir of 0.6 1.1 nmol/mL, but rebounded to a mean maximum free digoxin concentration of 1.7 1.3 nmol/mL in 77 46 hours. The time to maximum free digoxin rebound occurred later in patients with end-stage renal disease (n = 4) compared with other patients (127 40 hours compared with 55 28 hours).

Conclusion: Elimination of digoxin following Fab therapy is prolonged in digoxin-toxic patients with renal dysfunction. In addition, rebound of free digoxin is delayed in anephric patients. Monitoring free digoxin following the administration of Fab may be of value in selected patients to guide additional Fab dosing, confirm possible rebound toxicity, or guide the reinitiation of digoxin therapy.

Figures

Grahic Jump Location
Figure 1.
Disposition of free and total digoxin time profiles.open circlesclosed circles

Total ( ) and free ( ) digoxin concentrations, and free fraction (closed triangles) time profile for patients 2, 6, 10, and 12. The arrows shown for patients 2, 6, and 10 represent the time at which suspected digoxin reintoxication occurred with respect to the free digoxin concentration. The arrow for patient 12 represents the time when digoxin therapy was reinitiated with respect to the free digoxin concentration.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Journal Club
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)